These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11585158)

  • 21. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
    Karikios DJ; Chim L; Martin A; Nagrial A; Howard K; Salkeld G; Stockler MR
    Intern Med J; 2017 Apr; 47(4):400-407. PubMed ID: 27928875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmac dogma.
    Douglas B
    N Z Med J; 2007 Feb; 120(1249):U2430. PubMed ID: 17308566
    [No Abstract]   [Full Text] [Related]  

  • 24. Heterogeneity of heart failure management programs in Australia.
    Driscoll A; Worrall-Carter L; McLennan S; Dawson A; O'Reilly J; Stewart S
    Eur J Cardiovasc Nurs; 2006 Mar; 5(1):75-82. PubMed ID: 16216559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Difficult standpoints to be taken by the committee of costs and subsidies].
    Persson U; Anell A; Jendteg S
    Lakartidningen; 2002 Jul; 99(30-31):3128-9. PubMed ID: 12198933
    [No Abstract]   [Full Text] [Related]  

  • 27. Access to medicines and global health: will Canada lead or flounder?
    Orbinski J
    CMAJ; 2004 Jan; 170(2):224-6. PubMed ID: 14734437
    [No Abstract]   [Full Text] [Related]  

  • 28. Hard decisions about fundamental values.
    Laupacis A
    Healthc Pap; 2004; 4(3):60-6; discussion 68-72. PubMed ID: 15114071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recognize the role of employers.
    French M
    Healthc Pap; 2004; 4(3):46-50; discussion 68-72. PubMed ID: 15114069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else.
    Dalton A
    Aust Health Rev; 2001; 24(2):7-14. PubMed ID: 11496474
    [No Abstract]   [Full Text] [Related]  

  • 31. A review of limited lists and formularies: are they cost-effective?
    Pearce MJ; Begg EJ
    Pharmacoeconomics; 1992 Mar; 1(3):191-202. PubMed ID: 10147029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study.
    Harris A; Li JJ; Yong K
    Pharmacoeconomics; 2016 Apr; 34(4):393-402. PubMed ID: 26610347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National pharmacare: a dog's tale.
    Anis AH
    CMAJ; 2004 Sep; 171(6):565-6. PubMed ID: 15367455
    [No Abstract]   [Full Text] [Related]  

  • 35. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.
    Morgan SG; McMahon M; Mitton C; Roughead E; Kirk R; Kanavos P; Menon D
    Health Aff (Millwood); 2006; 25(2):337-47. PubMed ID: 16522575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inadequate prescription-drug coverage for Medicare enrollees--a call to action.
    Soumerai SB; Ross-Degnan D
    N Engl J Med; 1999 Mar; 340(9):722-8. PubMed ID: 10053183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Medication prices in Germany--how are they determined?].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
    [No Abstract]   [Full Text] [Related]  

  • 40. Patient access to pharmaceuticals: an international comparison.
    Cohen J; Faden L; Predaris S; Young B
    Eur J Health Econ; 2007 Sep; 8(3):253-66. PubMed ID: 17279403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.